"Bringing this latest technology to our center is in the best interest of men facing a prostate cancer diagnosis," said Scott Herbert, M.D., chief, Radiation Oncology.
Abington, PA (PRWEB) May 24, 2011
Abington Memorial Hospital announced the installation of a Calypso® System at its Rosenfeld Cancer Center, a leading cancer center in suburban Philadelphia. Calypso will provide prostate cancer patients with the benefits of accurate, precise, real-time tumor tracking during external beam radiation therapy delivery.
“The Calypso System is an important new tool in the treatment of prostate cancer,” said Scott Herbert, M.D., chief of Radiation Oncology at The Rosenfeld Cancer Center. “Bringing this latest technology to our center is in the best interest of men facing a prostate cancer diagnosis.”
With its GPS for the Body® technology, the Calypso System utilizes miniature implanted Beacon® transponders to provide precise, continuous information on the location of the tumor during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit adjacent healthy tissue.
In contrast to other tumor targeting solutions, the Calypso System provides real-time tumor position information, thereby allowing physicians to deliver radiation directly to the tumor while sparing the surrounding healthy organs from exposure. In contrast to other guidance techniques, Calypso’s electromagnetic technology is the only non-ionizing guidance solution to keep the treatment precisely focused on the prostate or post-operative prostatic bed without adding unnecessary radiation.
According to the American Cancer Society, each year more than 200,000 men in the United States are diagnosed with prostate cancer. In men in the United States, it is the leading cancer diagnosis and is the second most common cause of cancer death after lung cancer.
A recent clinical study entitled, “Assessing the Impact of Margin Reduction (AIM),” published in Urology, demonstrated that prostate tumor tracking utilizing the Calypso System during high-dose intensity-modulated radiotherapy (IMRT) allowed physicians to deliver a higher dose of radiation with smaller planning treatment volume (PTV) margins, while reducing treatment-related side effects.
The Calypso System is installed in over 100 leading cancer centers worldwide including: Memorial Sloan-Kettering Cancer Center, University of Washington Medical Center, and Duke University Medical Center.
About Abington Memorial Hospital
Abington Memorial Hospital is a 665-bed, acute care teaching hospital with a medical staff of more than 1,100 physicians and 5,600 employees. These professionals provide medical care and health services to residents of Bucks, Montgomery and Philadelphia counties. A regional provider, Abington Memorial Hospital has the only Level II accredited trauma center in Montgomery County and offers highly specialized services in cardiac care, cancer care, neurosciences, orthopaedics and maternal/child health.
About Calypso Medical
Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional information can be found at http://www.calypsomedical.com.